TrovaGene, Inc. (TROV) - NASDAQ
  • Fri, Jun. 10, 12:48 PM
    | Fri, Jun. 10, 12:48 PM | 2 Comments
  • Fri, Jun. 10, 11:00 AM
    | Fri, Jun. 10, 11:00 AM
  • Tue, May 10, 4:22 PM
    • TrovaGene (NASDAQ:TROV): Q1 EPS of -$0.36 misses by $0.07.
    • Revenue of $0.12M (-7.7% Y/Y) misses by $0.14M.
    • Shares are up 13% premarket but only on turnover of 1,500 shares.
    • Press Release
    | Tue, May 10, 4:22 PM | 1 Comment
  • Mon, May 9, 9:56 AM
    • Laboratory Corporation of America (LH +0.9%) launches Epi proColon, the first FDA-approved DNA-based blood test for colorectal cancer (CRC) screening. The product was developed by Epigenomics AG (OTCQX:EPGNF)(OTCQX:EPGNY) and is available under a joint commercialization agreement with Polymedco in North America.
    • Epi proColon detects a DNA methylation biomarker for CRC called Septin9 in cell-free DNA circulating in the blood. The FDA approved it on April 13.
    • CRC screening-related tickers: (EXAS +3.7%)(VNRX +0.3%)(TBIO +9.6%)(SQNM +1.8%)(BIOC +2.8%)(OTCQX:RHHBY +2.2%)(CHEK +20.8%)(TROV +0.6%)
    | Mon, May 9, 9:56 AM | 7 Comments
  • Fri, Apr. 29, 4:12 PM
    • Medtronic (MDT -0.8%) initiated with Buy rating and $93 (18% upside) price target by SunTrust Robinson Humphrey.
    • Celator Pharmaceuticals (CPXX +1.5%) initiated with Buy rating and $23 (53% upside) price target by Stifel Nicolaus.
    • Caladrius Biosciences (CLBS -1%) upgraded to Buy from Neutral by H.C. Wainwright with a price target of $1.25 (81% upside).
    • Insulet (PODD -0.6%) upgraded to Outperform from Market Perform by William Blair with a $40 (21% upside) price target.
    • Alexion Pharmaceuticals (ALXN -2.3%) upgraded to Outperform from Market Perform by BMO Capital with a $168 (21% upside) price target.
    • ResMed (RMD -1.2%) upgraded to Neutral from Underperform by Macquarie. Price target lowered to $57 (2% upside) from $65.
    • Stryker (SYK -0.5%) upgraded to Buy from Neutral by Sterne Agee CRT with $130 (19% upside) price target.
    • Jazz Pharmaceuticals (JAZZ -0.9%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $200 (32% upside) from $164.
    • Rigel Pharmaceuticals (RIGL -1.7%) upgraded to Overweight from Neutral by JP Morgan with a $5 price target.
    • Novartis (NVS -1.1%) upgraded to Equal Weight from Underweight by Barclays.
    • Molina Healthcare (MOH -19.4%) downgraded to Neutral from Buy by UBS. Price target lowered to $54 (4% upside) from $76.
    • St. Jude Medical (STJ -2%) downgraded to Neutral from Overweight by JP Morgan. Price target raised to $82.50 (9% upside) from $66.
    • Stericycle (SRCL -21.5%) downgraded to Underperform from Sector Perform by RBC. Price target lowered to $96 (1% upside) from $119.
    • Sarepta Therapeutics (SRPT +2.8%) downgraded to Underperform from Hold by Jefferies with a price target of $7 (51% downside risk). Downgraded to Underweight from Neutral by Piper Jaffray. Price target lowered to $6 (57% downside risk) from $15.
    • Perrigo (PRGO +0.3%) downgraded to Neutral from Buy by BTIG Research. Priced target removed.
    • Trovagene (TROV -3.6%) downgraded to Hold from Buy by Cantor Fitzgerald with a $6 (50% upside) price target.
    • Community Health Systems (CYH -4.6%) downgraded to Underperform from Market Perform by Raymond James with a $19 (0% upside) price target.
    | Fri, Apr. 29, 4:12 PM | 5 Comments
  • Mon, Apr. 25, 12:47 PM
    | Mon, Apr. 25, 12:47 PM | 20 Comments
  • Mon, Apr. 25, 8:52 AM
    • Trovagene (NASDAQ:TROV) appoints former Sequenom (NASDAQ:SQNM) chief Bill Welch as CEO effective immediately. He replaces Dr. Antonius Schuh, who was fired last month over a breach of fiduciary duty.
    • Separately, Chief Commercial Officer Matthew Posard has left the firm.
    | Mon, Apr. 25, 8:52 AM | 7 Comments
  • Mon, Apr. 4, 12:32 PM
    • Thinly traded micro cap OncoCyte (OCX +39.8%) is up on almost a 5x surge in volume, albeit on turnover of less than 100K shares, in response to its announcement of a successful 620-subject research study on its lung cancer diagnostic test that validates the transition of the assay platform from Illumina (ILMN +1.3%) microarrays to a Nanostring (NSTG -2.3%nCounter instrument, the platform OncoCyte intends to use for commercialization. The study, which replicates an earlier one, was conducted by biomedical research organization The Wistar Institute.
    • The company will now independently validate the results with its own follow-up study. If successful, it will execute the necessary analytic work to support the test's commercialization. If all goes well, commercial launch could happen in H1 2017. When launched, it will be the first commercially available, non-invasive diagnostic for the early detection of lung cancer.
    • The value proposition of liquid biopsy, performed on a peripheral blood sample, is lower cost, greater convenience and much more patient-friendly that traditional tissue biopsy.
    • Related tickers: (TROV +2.1%)(TBIO +5%)(SQNM)(CDNA -1.2%)(ILMN +1.3%)(FMI +3%)(BIOC -0.8%)
    | Mon, Apr. 4, 12:32 PM | 5 Comments
  • Tue, Mar. 29, 12:49 PM
    | Tue, Mar. 29, 12:49 PM | 3 Comments
  • Tue, Mar. 29, 9:18 AM
    | Tue, Mar. 29, 9:18 AM | 3 Comments
  • Mon, Mar. 28, 7:36 PM
    • Trovagene (TROV -1.7%) says it's terminated its chief executive officer and chief financial officer for cause.
    • The company's board fired CEO Antonius Schuh and CFO Stephen Zaniboni and has filed a court complaint that includes a charge of breach of fiduciary duty.
    • Shares are down 2.2% after hours.
    • Trovagene says the pair failed to present a "lucrative corporate opportunity" to the board and instead took the opportunity for personal benefit. The company's asking them to turn over their interests in the new therapeutics.
    • Chairman Thomas Adams is serving as interim CEO, effective immediately. He's been chairman since April 2009.
    • Update: The company has filed a complaint in the Superior Court of State of California for the County of San Diego demanding that Dr. Schuh and Mr. Zaniboni turn over their interests in the new therapeutics to Trovagene.
    | Mon, Mar. 28, 7:36 PM | 12 Comments
  • Thu, Mar. 10, 4:23 PM
    • TrovaGene (NASDAQ:TROV): Q4 EPS of -$0.26 misses by $0.01.
    • Revenue of $0.1M (+66.7% Y/Y) in-line.
    • Press Release
    | Thu, Mar. 10, 4:23 PM
  • Wed, Mar. 9, 8:20 AM
    • Thinly traded nano cap Biocept (NASDAQ:BIOC) closes a contract with preferred provider organization (PPO) FedMed for access to its Target Selector liquid biopsy testing.
    • FedMed, founded in 2000, provides medical services access to over 40M Americans through its PPO of more than 550K doctors, 4K hospitals and 60K ancillary care providers.
    • Biocept's testing detects circulating tumor DNA (ctDNA) in a peripheral blood sample obtained via a routine blood draw. Tumors consistently shed bits of DNA that circulate in the blood which has potential for detecting and monitoring cancer. Because the amounts of ctDNA are very small, the clinical utility wasn't there until high powered sequencers became available, such as those made by Illumina (NASDAQ:ILMN). The value proposition of liquid biopsy is lower cost, greater convenience and much more patient-friendly that traditional tissue biopsy.
    • Shares are up 13% premarket on light volume.
    • Liquid biopsy-related tickers: (NASDAQ:TROV)(NASDAQ:TBIO)(NASDAQ:SQNM)(NASDAQ:CDNA)
    • Previously: Biocept's liquid biopsy matches 93% of lung cancer tissue biopsies in study (Feb. 26)
    | Wed, Mar. 9, 8:20 AM | 5 Comments
  • Wed, Mar. 2, 11:19 AM
    • Birmingham, AL-based Circulogene Theranostics announces that it has received its first international orders for its liquid biopsy tests that only require a single drop of blood. The company's tests, launched less than three months ago, detect cell-free DNA (cfDNA) associated with 10 tumor types, including breast, lung and colon cancer.
    • According to the privately held company, its proprietary method enables it to collect 100 times more cfDNA compared to the industry standard with 1/10 the sample size (~20 microliters) because it avoids the loss of cfDNA that typically occurs in the extraction and isolation steps.
    • Its liquid biopsy testing can detect almost 3,000 cancer mutations on 50 well-established cancer-related genes in its 10 cancer profiles.
    • Related tickers: (TROV +1.6%)(TBIO -1.3%)(SQNM)(BIOC -1.4%)(CDNA -1.2%)(ILMN -0.6%)
    | Wed, Mar. 2, 11:19 AM | 1 Comment
  • Fri, Feb. 26, 11:02 AM
    • Results from a recent study show Biocept's (BIOC +2%) liquid biopsy test that detects bits of tumor-related DNA in the blood agreed with tissue biopsy results 93% of the time in 74 lung cancer patients. The data were presented in a poster session at the UCSD Moores Cancer Center Industry/Academia Translational Oncology Symposium in San Diego, CA.
    • Biocept's test detects circulating tumor DNA (ctDNA) in a peripheral blood sample obtained via a routine blood draw. Tumors consistently shed bits of DNA that circulate in the blood which has potential for detecting and monitoring cancer. Because the amounts of ctDNA are very small, the clinical utility wasn't there until high powered sequencers became available, such as those made by Illumina (ILMN +1.4%). The value proposition of liquid biopsy is lower cost, greater convenience and much more patient-friendly that traditional tissue biopsy.
    • Related tickers: (TROV -4.5%)(TBIO +6.6%)(SQNM -2.1%)(CDNA +2.8%)
    | Fri, Feb. 26, 11:02 AM | 18 Comments
  • Wed, Feb. 24, 8:52 AM
    • Trovagene (NASDAQ:TROV) secures coverage of its Precision Cancer Monitoring (PCM) services by Three Rivers Provider Network. The Chula Vista, CA-based organization covers 14M people.
    • Trovagene's proprietary technology is focused on the detection of cell-free DNA (cfDNA) in urine as a potential method of managing cancer. Its value proposition is a less invasive way to monitor and detect cancer compared to tissue biopsy while being less expensive, more convenient and much more patient-friendly.
    | Wed, Feb. 24, 8:52 AM | 3 Comments
Company Description
Trovagene, Inc. is a development stage molecular diagnostic company that focuses on the development and commercialization of a proprietary urine-based molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. Its primary internal focus... More
Sector: Healthcare
Industry: Biotechnology
Country: United States